TriangleNCT00074165 · OUTCOME
Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- 5 years
What was measured
Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.
Analysis population: Data not collected due to low accrual and early termination.
Groups in this outcome
Rituximab and Carboplatin
Rituximab: (i.v.) 375 mg/m\^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m\^2 /day x 2 days = 400 mg/m\^2
| Group | Source count |
|---|---|
| Rituximab and Carboplatin | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.
- groups
- description
- Rituximab: (i.v.) 375 mg/m\^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m\^2 /day x 2 days = 400 mg/m\^2
- id
- OG000
- title
- Rituximab and Carboplatin
- population Description
- Data not collected due to low accrual and early termination.
- reporting Status
- POSTED
- time Frame
- 5 years
- title
- Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice